Inventor · disambiguated record
Thomas James Hill
Also filed as: HILL THOMAS · HILL THOMAS J · HILL THOMAS JAMES
10 granted patents·150 citations·filing 2009–2022
90Inventor score
Top patents by PatentIndex Score
10 records- 0197US11318109B2Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)GW PHARMA LTD·Filed 2019·Granted May 3, 2022·17 cites·42 claims
- 0296US12121499B2Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)GW PHARMA LTD·Filed 2022·Granted Oct 22, 2024·3 cites·22 claims
- 0395US9962341B2Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancerGW PHARMA LTD·Filed 2015·Granted May 8, 2018·27 cites·9 claims
- 0493US10729665B2Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)WHALLEY BENJAMIN·Filed 2012·Granted Aug 4, 2020·25 cites·11 claims
- 0593US9200007B2Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitorsSHUTTLEWORTH STEPHEN JOSEPH·Filed 2010·Granted Dec 1, 2015·22 cites·6 claims
- 0692US8981087B2Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitorsSHUTTLEWORTH STEPHEN JOSEPH·Filed 2010·Granted Mar 17, 2015·26 cites·11 claims
- 0791US9580442B2Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitorsKARUS THERAPEUTICS LTD·Filed 2015·Granted Feb 28, 2017·14 cites·5 claims
- 0890US9938290B2Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitorsKARUS THERAPEUTICS LTD·Filed 2017·Granted Apr 10, 2018·11 cites·3 claims
- 0988US10501478B2Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitorsKARUS THERAPEUTICS LTD·Filed 2018·Granted Dec 10, 2019·5 cites·7 claims
- 1052US8614193B2Depsipeptides and their therapeutic useSHUTTLEWORTH STEPHEN JOSEPH·Filed 2009·Granted Dec 24, 2013·0 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when Thomas James Hill files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →